Maria Celeste Osório Wender

Maria Celeste Osório Wender

Auto-generated profile, based on publicly available information

Maria Celeste Osório Wender

Universidade Federal do Rio Grande do Sul Porto AlegreRS Brazil Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

13 November 2017 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
AHAline Henz
Aline Henz
Charles Francisco FerreiraCharles Francisco Ferreira
Charles Francisco Ferreira
COCarolina Leão Oderich
Carolina Leão Oderich
CGCarin Weirich Gallon
Carin Weirich Gallon
JCJuliana Rintondale Sodré de Castro
Juliana Rintondale Sodré de Castro
MWMaria Celeste Osório Wender
Maria Celeste Osório Wender
Objective To validate the premenstrual symptoms screening tool (PSST) in relation to the daily record of severity of problems (DRSP) for premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) diagnoses. Methods A cross-sectional study with 127 women (20–45 years) with PMS complaints. The women were evaluated in terms of weight, height and body mass index (BMI). After using the primary care evaluation of mental disorders (PRIME-MD) questionnaire to exclude the diagnosis of depression, the PSST was completed and the women were instructed to fill out the DRSP for two consecutive menstrual cycles. The agreement between the two questionnaires was assessed by the Kappa (k) and the prevalence-adjusted, bias-adjusted kappa (PABAK) values. Results Two-hundred and eighty-two women met the eligibility criteria and answered the PSST. The DRSP was completed for two cycles by 127 women. The percentages of women with PMS and PMDD diagnoses by the DRSP were 74.8% and 3.9% respectively; by PSST, the percentages were41.7% and 34.6% respectively. The number of patients considered “normal” (with symptoms below the threshold for the diagnosis of PMS) was similar in both questionnaires. There was no agreement (Kappa = 0.12) in the results of PMS/ PMDD diagnosis (the PABAK coefficient confirmed this result = 0.39). The PSST had a high sensitivity (79%) and a low specificity (33.3%) for PMS/PMDD diagnosis. Conclusion The PSST should be considered a diagnostic screening tool. Positive PMS/PMDD cases by PSST should be further evaluated by DRSP to confirm the diagnosis.

1 January 2017 in Revista Brasileira de Reumatologia (English Edition)
Verified
Journal Article
Open access
SRSebastião Cézar Radominski
Sebastião Cézar Radominski
WBWanderley Bernardo
Wanderley Bernardo
APAna Patrícia de Paula
Ana Patrícia de Paula
BABen-Hur Albergaria
Ben-Hur Albergaria
CMCaio Moreira
Caio Moreira
VBVictoria Z.C. Borba
Victoria Z.C. Borba
Osteoporosis is the leading cause of fractures in the population older than 50 years. This silent disease affects primarily postmenopausal women and the elderly, and the morbidity and mortality rates are high. The main goal of treating osteoporosis is the prevention of fractures. The identification of populations at risk through early diagnosis and treatment is essential. The last Brazilian guideline for the treatment of postmenopausal osteoporosis was elaborated in 2002. Since then, new strategies for diagnosis and risk stratification have been developed, and drugs with novel action mechanisms have been added to the therapeutic arsenal. The Osteoporosis and Osteometabolic Diseases Committee of the Brazilian Society of Rheumatology, in conjunction with the Brazilian Medical Association and other Societies, has developed this update of the guidelines for the treatment of postmenopausal osteoporosis according to the best scientific evidence available. This update is intended for professionals in many medical and health specialties involved in the treatment of osteoporosis, for physicians in general and for health-related organizations.

20 March 2019 in Journal of Sex & Marital Therapy
Verified
Journal Article
Closed access
RSRenata Schvartzman
Renata Schvartzman
LSLuiza Schvartzman
Luiza Schvartzman
Charles Francisco FerreiraCharles Francisco Ferreira
Charles Francisco Ferreira
JVJanete Vettorazzi
Janete Vettorazzi
ABAdriane Bertotto
Adriane Bertotto
MWMaria Celeste Osório Wender
Maria Celeste Osório Wender
The dyspareunia negatively affects women´s quality of life, and is a frequent complaint during the peri and postmenopausal period. A randomized trial evaluated sexual function, quality of life, pain, and pelvic floor muscle function of climacteric women aged between 40-60 years-old, with complaints of dyspareunia for at least 6 months and being sexually active. They were assessed before and after their randomization in one of the following interventions: the first group (n = 21) received five one-hour sessions of thermotherapy for relaxation of pelvic floor muscles, myofascial release, and pelvic training (Pelvic Floor Muscle Training – PFMT group). The second group (n = 21) received five one-hour sessions during which heat was applied to the lower back with myofascial release of abdominal diaphragm, piriformis, and iliopsoas muscles, with no involvement of pelvic training (Lower Back – LB group). Forty-two climacteric women with dyspareunia (mean ± SD, PFMT group: 51.9 ± 5.3 years, LB group: 50.6 ± 4.7 years, Student’s t test, p = 0.397) were studied. Pain scores (mean ± SEM) in the PFMT group decreased from 7.77 ± 0.38 to 2.25 ± 0.30; and in the LB group from 7.62 ± 0.29 to 5.58 ± 0.49 (Generalized Estimating Equation – GEE model, p ≤ 0.001 for group, time, and interaction pairwise comparisons). Conclusion: The proposed pelvic floor muscle training protocol was effective to improve pain, quality of life, sexual function, and pelvic floor muscle function in climacteric women with dyspareunia.

1 September 2004 in Journal of Voice
Verified
Journal Article
Closed access
EMEliséa Maria Meurer
Eliséa Maria Meurer
MWMaria Celeste Osório Wender
Maria Celeste Osório Wender
HCHelena von Eye Corleta
Helena von Eye Corleta
ECEdison Capp
Edison Capp

1 May 2020 in The Lancet
Verified
Journal Article
Closed access
Alice PanchaudAlice Panchaud
Alice Panchaud
GFGuillaume Favre
Guillaume Favre
LPLeo Pomar
Leo Pomar
MVManon Vouga
Manon Vouga
KAKaroline Aebi-Popp
Karoline Aebi-Popp
NJNieto-Calvache Albaro José
Nieto-Calvache Albaro José